MedTrace Logo

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

NCT00103038 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2022-06-09

Study results available
· View outcomes & findings →

Summary

This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose brain tumors and find out how far the disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It may help visualize the blood flow going through the tumor better than the standard substance gadolinium-based contrast agent.

Conditions

  • Central Nervous System Lymphoma
  • Malignant Glioma
  • Metastatic Malignant Neoplasm in the Brain

Interventions

PROCEDURE

3 Tesla Magnetic Resonance Imaging

Undergo 3T MRI

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo 3T DCE-MRI

PROCEDURE

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo 3T DSC-MRI

DRUG

Ferumoxytol

Given IV

DRUG

Gadolinium

Given IV

PROCEDURE

MRI-Based Angiogram

Undergo MRA

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Edward Neuwelt · OHSU Knight Cancer Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-04
Primary Completion
2016-05-10
Completion
2016-06-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103038 on ClinicalTrials.gov